MartinEduardoGutierrezMD

Oncology • Hackensack, NJ

Director Drug Discovery/Phase I Research Chief of Thoracic Oncology Member of GI Division

Join to view full profile

Dr. Gutierrez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gutierrez's full profile

Already have an account?

Office
92 2nd Street
Hackensack, NJ 07601
Is this information wrong?

Summary

As co-chief, Thoracic Oncology, and director of the Phase 1 Program, I specialize in bringing Phase 1 clinical trials to cancer patients treated at John Theurer Cancer Center. The approximately 40 Phase 1 trials currently in place are focused on immunotherapy, targeted therapies, and cell technologies such as CAR-T therapy, which engineers T-cells to target cancer.

Martin Gutierrez, M.D., treats patients with lung and gastrointestinal cancers

Dr. Martin Gutierrez, co-chief, Thoracic Oncology and director, Phase 1 Program at John Theurer Cancer Center, treats patients with lung and gastrointestina...

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Boston University Medical CenterResidency, Internal Medicine, 1993 - 1996
Pontifical Xavierian UniversityClass of 1991

Certifications & Licensure

NY State Medical License 2021 - 2026
NJ State Medical License 2011 - 2025
FL State Medical License 2000 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum Start of enrollment: 2009 Mar 01
Completed
Phase 2
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Start of enrollment: 2018 Mar 07
Recruiting
Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Start of enrollment: 2013 Mar 01
Completed
Phase 1
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Start of enrollment: 2013 Apr 01
Terminated
Phase 1, Phase 2
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Start of enrollment: 2013 Nov 01
Completed
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air Start of enrollment: 2013 Oct 01
Unknown status
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment Start of enrollment: 2014 Apr 01
Completed
Phase 1
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Start of enrollment: 2014 Jul 01
Withdrawn
Phase 1
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Start of enrollment: 2017 Feb 23
Terminated
Phase 1
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2018 Oct 01
Completed
Phase 1, Phase 2
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Start of enrollment: 2019 May 17
Recruiting
Phase 1
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Start of enrollment: 2019 Sep 18
Recruiting
Phase 1, Phase 2
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations Start of enrollment: 2022 Apr 18
Active, not recruiting
Phase 1
Roles: Contact
A Study of SGN-EGFRd2 in Advanced Solid Tumors Start of enrollment: 2023 Nov 14
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

144 citations
Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Martin Gutierrez, Kelly Choi, Richard B. Lanman, Edward J. Licitra, Stanley M. Skrzypczak
Clinical Lung Cancer. 2017-04-13
2641 citations
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott
The New England Journal of Medicine. 2015-01-21
55 citations
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Pat...
Mark A. Socinski, Frederic J. Kaye, David R. Spigel, Fred J. Kudrik, Santiago Ponce
Clinical Lung Cancer. 2017-01-01

Lectures

Utilization of next generation sequencing (NGS) and rates of undergenotyping in patients with metastatic colon cancer (mCC) treated at academic and community centers i...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Rates of genotyping for , , , microsatellite instability (MSI), and mismatch repair (MMR) in metastatic colon cancer patients: Gaps and implications.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Join now to see all

Press Mentions

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of CancerSeptember 5th, 2022
Molecular Tumor Testing Transformative, yet 'Under-Optimized'July 23rd, 2021
NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19th, 2021
Join now to see all